Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present Antibe Therapeutics, Inc. (OTC: ATBPF).

Full DD Report for ATBPF

Recent News from (OTC: ATBPF)

Antibe Therapeutics Engages Blaise Group International for Executive Search
Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQB: ATBPF) has engaged Blaise Group International (“Blaise Group”), a leading healthcare-focused executive recruitment agency, to augment its global business development expertise. B...
Source: Business Wire
Date: April, 11 2018 20:00
Antibe Therapeutics provides financial update
Antibe Therapeutics ( OTCQB:ATBPF ) announces a successful Phase 2B clinical trial demonstrating the gastrointestinal safety of its lead drug, reports that the Company now has a significantly augmented balance sheet. More news on: Antibe Therapeutics, Inc., Healthcare stocks news, Re...
Source: SeekingAlpha
Date: April, 03 2018 08:31
Antibe Therapeutics Provides Financial Update
Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV:ATE, OTCQB:ATBPF), a leader in developing safer therapeutics for pain and inflammation that recently announced a successful Phase 2B clinical trial demonstrating the gastrointestinal safety of its lead dru...
Source: Business Wire
Date: April, 03 2018 07:00
Antibe: A Buy For Their GI-Safe Next-Generation NSAID Potential
Antibe's Answer to NSAIDs' Problem Non-Steroidal Anti-Inflammatory Drugs ( NSAIDs ) account for a very large category of drug sales globally (>$11B in 2014), helping millions around the world in their pain relief, be it chronic or acute. However, the current NSAIDs have serious g...
Source: SeekingAlpha
Date: March, 21 2018 09:43
Antibe's ATB-346 successful in mid-stage GI safety study; shares up 71%
Thinly traded micro cap Antibe Therapeutics ( OTCQB:ATBPF +71% ) is up on over a 6x surge in volume in response to its announcement of positive results from a Phase 2b gastrointestinal (GI) study of lead drug ATB-346. More news on: Antibe Therapeutics, Inc., Healthcare stocks news, Sto...
Source: SeekingAlpha
Date: March, 20 2018 11:10
Antibe Therapeutics Announces Successful Phase 2B Gastrointestinal Safety Study for Lead Pain Drug, ATB-346
Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQB: ATBPF) is pleased to announce that its lead drug, ATB-346, met its primary endpoint in the Phase 2B gastrointestinal (“GI”) safety study. The double-blind study was conducted in ...
Source: Business Wire
Date: March, 20 2018 08:35
Antibe continues up move ahead of key data readout, shares ahead 3%
Thinly traded nano cap Antibe Therapeutics ( OTCQB:ATBPF +3.3% ) is up on over triple volume, albeit on turnover of only 258K shares, ahead of its release of top-line data next week from a Phase 2b clinical trial evaluating the safety of lead drug ATB-346 (naproxen sodium) in 240 he...
Source: SeekingAlpha
Date: March, 13 2018 10:50
Antibe Therapeutics Announces No Material Change
Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQB: ATBPF) wishes to advise that it is not aware of any undisclosed material change in the Company’s activities that would account for recent market activity. As previously disclosed in its...
Source: Business Wire
Date: March, 13 2018 10:26
Antibe Therapeutics reports Q3 results
Antibe Therapeutics ( OTCQB:ATBPF ): Q3 EPS of C$0.01 Revenue of C$2.23M (+17.4% Y/Y) Press Release More news on: Antibe Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, ,
Source: SeekingAlpha
Date: February, 27 2018 23:07
Antibe Therapeutics Reports Q3 2018 Interim Financial and Operating Results
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF) filed its financial and operating results on Tuesday, February 27 th for the fiscal quarter ended December 31, 2017. The Company’s unaudited fiscal Q3 2018 condensed interim consolidated fina...
Source: Business Wire
Date: February, 27 2018 21:45

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-04-210.370.350130.37330.3501336,730
2018-04-200.370.350130.37330.3501336,730
2018-04-190.38090.36250.38090.362595,134
2018-04-180.3693590.380.38250.36916139,560
2018-04-170.365260.3920.3920.3652621,505

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-04-2016,51536,73044.9632Short
2018-04-1951,25395,13453.8745Short
2018-04-1827,66039,56069.9191Short
2018-04-1790021,5054.1851Cover
2018-04-167,40028,05526.3768Cover

* Short Mode

Short Analysis provided by Squeeze Report.


About Antibe Therapeutics, Inc. (OTC: ATBPF)

Logo for Antibe Therapeutics, Inc. (OTC: ATBPF)

Antibe is a commercial stage pharmaceutical company focused on pain, inflammation and regenerative medicine. Antibe s lead drug, ATB , targets the global need for a safer non steroidal anti inflammatory drug NSAID for treating chronic pain and inflammation with non addictive medication. Antibe s subsidiary, Citagenix Inc. Citagenix , is a leader in Canada in the sales and marketing of tissue regenerative products servicing the dental and orthopaedic marketplaces. Since its inception in , Citagenix has become an important source of knowledge and experience in the Canadian medical device industry. Citagenix has grown a comprehensive portfolio of high quality, branded biologics and medical devices that promote bone regeneration. Citagenix is active in countries, operating in Canada through its direct sales teams, and internationally via a network of distributor partnerships.

 

 

 

Current Management

  • Daniel Legault / CEO
  • John Wallace / CSO
  • Alain Wilson / CFO
  • Scott Curtis / VP, Business Development
  • David Vaughan / Chief Development Officer
  • Beth Chin / Finance Manager
  • Walt Macnee / Chairman
  • Roderick Flower /
  • Daniel Legault /
  • Samira Sakhia /
  • John Wallace /

Current Share Structure

  • Market Cap: $41,059,615 - 03/16/2018
  • Issue and Outstanding: 162,967,313 - 12/31/2017
  • Float: 121,474,519 - 09/08/2017

 


Recent Filings from (OTC: ATBPF)

Management Discussion and Analysis - Management's Discussion and Analysis for the Three and Nine Months ended December 31, 2017
Filing Type: Management Discussion and Analysis - Management's Discussion and Analysis for the Three and Nine MonFiling Source: OTC Markets
Filing Date: February, 27 2018
Interim Financial Report - Interim Consolidated Financial Statements For the Three and Nine Months ended December 31, 2017 and 2016
Filing Type: Interim Financial Report - Interim Consolidated Financial Statements For the Three and Nine Months eFiling Source: OTC Markets
Filing Date: February, 27 2018
Management Discussion and Analysis - Management's Discussion and Analysis for the Three and Six Months ended September 30, 2017
Filing Type: Management Discussion and Analysis - Management's Discussion and Analysis for the Three and Six MontFiling Source: OTC Markets
Filing Date: November, 29 2017
Interim Financial Report - Interim Consolidated Financial Statements For the Three and Six Months ended September 30, 2017 and 2016
Filing Type: Interim Financial Report - Interim Consolidated Financial Statements For the Three and Six Months enFiling Source: OTC Markets
Filing Date: November, 29 2017
OTCQB Certification - OTCQB Certification
Filing Type: OTCQB Certification - OTCQB CertificationFiling Source: OTC Markets
Filing Date: September, 08 2017
Management Discussion and Analysis - Management's Discussion and Analysis for the three months ended June 30, 2017
Filing Type: Management Discussion and Analysis - Management's Discussion and Analysis for the three months endedFiling Source: OTC Markets
Filing Date: August, 29 2017
Quarterly Report - Interim Consolidated Financial Statements For the Three months ended June 30, 2017 and 2016
Filing Type: Quarterly Report - Interim Consolidated Financial Statements For the Three months ended June 30, 201Filing Source: OTC Markets
Filing Date: August, 29 2017
Supplemental Information - 2017 Annual Information Form
Filing Type: Supplemental Information - 2017 Annual Information FormFiling Source: OTC Markets
Filing Date: July, 29 2017
Management Discussion and Analysis - 2017 Fiscal Year MD&A
Filing Type: Management Discussion and Analysis - 2017 Fiscal Year MD&AFiling Source: OTC Markets
Filing Date: July, 29 2017
Annual Report - 2017 Audited Financial Statements
Filing Type: Annual Report - 2017 Audited Financial StatementsFiling Source: OTC Markets
Filing Date: July, 29 2017

 

 


Daily Technical Chart for (OTC: ATBPF)

Daily Technical Chart for (OTC: ATBPF)


Stay tuned for daily updates and more on (OTC: ATBPF)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: ATBPF)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

Monsta Trader
@MonstaTrader

 

 


Disclaimer: Monsta Trader publishes reports providing information on selected companies. Monsta Trader is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. Monsta Trader accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ATBPF is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. Monsta Trader has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. Monsta Trader does not own any shares of ATBPF and does not buy, sell, or trade any shares of ATBPF. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2016 by Monsta Trader. All rights reserved. Our Full Disclaimer: http://monstatrader.com/disclaimer/

 

 

Release this Report to Investors

Via Email

Via Text

Important

If you would like to schedule the release please Contact Us and we will assist you otherwise we will release this report to investors 15 minutes after payment is received to allow the most current information to be updated before the report is sent. Interested in reaching more investors? Contact Us